Used as a key intermediate in the synthesis of cyclin-dependent kinase (CDK) inhibitors, particularly in the development of anticancer agents. Its structure enables selective binding to CDK2 and CDK4 enzymes, which play critical roles in cell cycle regulation. This compound is especially valuable in targeted cancer therapies where dysregulation of the cell cycle is a hallmark, such as in breast cancer, leukemia, and melanoma. It has also been employed in structure-activity relationship (SAR) studies to optimize potency and selectivity of kinase inhibitors. Due to its bromine functional group, it serves as a versatile handle for further chemical modifications via cross-coupling reactions, facilitating the creation of diverse analogs for drug discovery.